Mark R. Dybul (born September 23, 1963) is an American diplomat, physician and medical researcher. He served as the executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria from 2012 until 2017.[2] Since 2021, he has been the CEO of Renovaro Biosciences.[3] Since 2022, he is the Executive Chairman of Purpose Life Sciences.[4]
Mark R. Dybul with Laura Bush during his swearing-in on October 10, 2006
Dybul was asked to stay on temporarily during the Barack Obama presidency transition, but was required to resign following the administration change, as he was a political appointee of the Bush administration.[6] On November 15, 2012, he was appointed the next executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria.[10] His selection as executive director by the Global Fund's board during its 28th meeting in Geneva was met with praise from both donors and the development community. World Bank President Jim Yong Kim called Dybul's appointment a "superb choice for a crucial role".[11] In an interview published in the Global Fund's digital newsletter, Dybul said his role as the Global Fund's new head "will be to maintain the strong forward trajectory of the Fund in order to end the three diseases".[12] He assumed his role of head of the Global Fund in February 2013.
Dybul is a professor in the department of medicine at the Medical Center of Georgetown University and the codirector of the Center for Global Health Practice and Impact. He is a member of the Global Health Initiative faculty committee.[13] From 2020 until 2022, Dybul served as a member of the Independent Panel for Pandemic Preparedness and Response, a group examining how the World Health Organization and countries handled the COVID-19 pandemic, co-chaired by Helen Clark and Ellen Johnson Sirleaf.[14] In the preparations for the Global Health Summit hosted by the European Commission and the G20 in May 2021, he was a member of the event's High Level Scientific Panel.[15]
Dybul has been an executive vice-chairman of Enochian Biosciences, a US biotechnology company, since 2019, before being appointed as its CEO in 2021.[16] Enochian changed its name to Renovaro Biosciences on August 14, 2023 following allegations that the company's founder was involved in a murder for hire scheme.[17]
Dybul serves on the boards of the Clinton Health Access Initiative, IAVI, Big Win Philanthropy, the Elton John AIDS Foundation, and Global Health Corps. [18][19][20][21][22][23][24][25]
